PROGYNY INC (PGNY) Stock Fundamental Analysis
USA - NASDAQ:PGNY - US74340E1038 - Common Stock
21.77 USD
-0.36 (-1.63%)
21.77 USD
0 (0%)
PGNY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. PGNY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PGNY is not valued too expensively and it also shows a decent growth rate. These ratings could make PGNY a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
In the past year PGNY had a positive cash flow from operations.
Each year in the past 5 years PGNY has been profitable.
Each year in the past 5 years PGNY had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 6.98%, PGNY belongs to the best of the industry, outperforming 89.11% of the companies in the same industry.
PGNY has a better Return On Equity (10.31%) than 75.25% of its industry peers.
PGNY has a Return On Invested Capital of 10.87%. This is amongst the best in the industry. PGNY outperforms 82.18% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PGNY is in line with the industry average of 9.19%.
The 3 year average ROIC (8.25%) for PGNY is below the current ROIC(10.87%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.98% | ||
| ROE | 10.31% | ||
| ROIC | 10.87% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
1.3 Margins
Looking at the Profit Margin, with a value of 4.28%, PGNY is in the better half of the industry, outperforming 74.26% of the companies in the same industry.
In the last couple of years the Profit Margin of PGNY has declined.
PGNY has a better Operating Margin (6.18%) than 64.36% of its industry peers.
In the last couple of years the Operating Margin of PGNY has grown nicely.
PGNY has a Gross Margin (22.34%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of PGNY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.18% | ||
| PM (TTM) | 4.28% | ||
| GM | 22.34% |
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PGNY is creating some value.
The number of shares outstanding for PGNY has been reduced compared to 1 year ago.
Compared to 5 years ago, PGNY has more shares outstanding
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PGNY has an Altman-Z score of 7.45. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PGNY (7.45) is better than 91.09% of its industry peers.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 7.45 |
ROIC/WACC1.25
WACC8.69%
2.3 Liquidity
A Current Ratio of 2.70 indicates that PGNY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.70, PGNY belongs to the top of the industry, outperforming 82.18% of the companies in the same industry.
PGNY has a Quick Ratio of 2.70. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PGNY (2.70) is better than 82.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 |
3. Growth
3.1 Past
PGNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.35%.
Measured over the past years, PGNY shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.77% on average per year.
The Revenue has grown by 9.62% in the past year. This is quite good.
The Revenue has been growing by 38.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%
3.2 Future
Based on estimates for the next years, PGNY will show a very strong growth in Earnings Per Share. The EPS will grow by 32.47% on average per year.
PGNY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.86% yearly.
EPS Next Y7.88%
EPS Next 2Y33.27%
EPS Next 3Y29.43%
EPS Next 5Y32.47%
Revenue Next Year9.74%
Revenue Next 2Y9.58%
Revenue Next 3Y10.09%
Revenue Next 5Y8.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 36.90, PGNY can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as PGNY.
The average S&P500 Price/Earnings ratio is at 27.20. PGNY is valued slightly more expensive when compared to this.
The Price/Forward Earnings ratio is 21.50, which indicates a rather expensive current valuation of PGNY.
PGNY's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of PGNY to the average of the S&P500 Index (22.71), we can say PGNY is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.9 | ||
| Fwd PE | 21.5 |
4.2 Price Multiples
PGNY's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PGNY indicates a rather cheap valuation: PGNY is cheaper than 87.13% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.84 | ||
| EV/EBITDA | 17.26 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PGNY does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PGNY may justify a higher PE ratio.
A more expensive valuation may be justified as PGNY's earnings are expected to grow with 29.43% in the coming years.
PEG (NY)4.68
PEG (5Y)N/A
EPS Next 2Y33.27%
EPS Next 3Y29.43%
5. Dividend
5.1 Amount
No dividends for PGNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.77
-0.36 (-1.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners100.04%
Inst Owner Change1.77%
Ins Owners1.36%
Ins Owner Change0.04%
Market Cap1.87B
Analysts80
Price Target29.29 (34.54%)
Short Float %8.74%
Short Ratio6.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.43%
Min EPS beat(2)-11.77%
Max EPS beat(2)14.63%
EPS beat(4)2
Avg EPS beat(4)-0.31%
Min EPS beat(4)-19.12%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)9.53%
EPS beat(12)9
Avg EPS beat(12)48.1%
EPS beat(16)13
Avg EPS beat(16)104.01%
Revenue beat(2)2
Avg Revenue beat(2)2.57%
Min Revenue beat(2)1.96%
Max Revenue beat(2)3.19%
Revenue beat(4)3
Avg Revenue beat(4)1.39%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.57%
Revenue beat(12)7
Avg Revenue beat(12)0.46%
Revenue beat(16)8
Avg Revenue beat(16)-0.53%
PT rev (1m)5.24%
PT rev (3m)7.49%
EPS NQ rev (1m)15.73%
EPS NQ rev (3m)21.8%
EPS NY rev (1m)10.16%
EPS NY rev (3m)3.19%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)2.23%
Revenue NY rev (3m)2.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.9 | ||
| Fwd PE | 21.5 | ||
| P/S | 1.51 | ||
| P/FCF | 9.84 | ||
| P/OCF | 9.27 | ||
| P/B | 3.63 | ||
| P/tB | 3.83 | ||
| EV/EBITDA | 17.26 |
EPS(TTM)0.59
EY2.71%
EPS(NY)1.01
Fwd EY4.65%
FCF(TTM)2.21
FCFY10.16%
OCF(TTM)2.35
OCFY10.79%
SpS14.44
BVpS5.99
TBVpS5.68
PEG (NY)4.68
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.98% | ||
| ROE | 10.31% | ||
| ROCE | 14.2% | ||
| ROIC | 10.87% | ||
| ROICexc | 24.96% | ||
| ROICexgc | 28.14% | ||
| OM | 6.18% | ||
| PM (TTM) | 4.28% | ||
| GM | 22.34% | ||
| FCFM | 15.31% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score8
Asset Turnover1.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 293.7% | ||
| Cap/Sales | 0.95% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 250.02% | ||
| Profit Quality | 358.02% | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 | ||
| Altman-Z | 7.45 |
F-Score8
WACC8.69%
ROIC/WACC1.25
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.35%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y7.88%
EPS Next 2Y33.27%
EPS Next 3Y29.43%
EPS Next 5Y32.47%
Revenue 1Y (TTM)9.62%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.47%
Revenue Next Year9.74%
Revenue Next 2Y9.58%
Revenue Next 3Y10.09%
Revenue Next 5Y8.86%
EBIT growth 1Y7.81%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year28.01%
EBIT Next 3Y18.46%
EBIT Next 5Y15.38%
FCF growth 1Y14.92%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y19.24%
OCF growth 3Y90.18%
OCF growth 5YN/A